EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Portal Vein Tryptophan Pathway Analysis Reveals Gut‐Mediated Inflammatory Pathway Predominance in HCV Infection

Jenna L Oringher iD, Rownock Afruza, Moumita Chakraborty, Kareen L Akiva, Grace Y Zhang, Elizabeth C Townsend iD, Gabriella M Quinn iD, Lisa Scheuing, Matthew G Menkart iD, Anjali Rai, David E Kleiner iD, Elliot B Levy und 4 weitere

Liver International · 2026-04 · 46 (4)

DOI: 10.1111/liv.70584 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Liver International, online erschienen am 10.03.2026. Verfasst von Jenna L Oringher und 15 weiteren Autor:innen. Beteiligte Einrichtung: Translational Hepatology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland…. Hauptthemen laut MEDLINE: Hepatitis C, Hepatitis C, Chronic, Portal Vein, Tryptophan. Die Arbeit nennt 40 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The tryptophan pathway is an integral component of the gut‐liver axis; however, the role in hepatitis C virus infection (HCV) and liver disease progression remains poorly understood. This study investigated tryptophan metabolites in portal and peripheral serum during and after HCV, and their relationship to inflammatory and clinical markers.

Methods

HCV infected patients were evaluated during infection (HCVi, n = 24) and 6 months after sofosbuvir/velpatasvir mediated sustained virologic response (SVR, n = 19) (NCT02400216). Liver biopsies, portal and peripheral blood collection, and stool sampling were performed at both time points. Statistical analyses assessed metabolite abundance during infection and recovery, and their associations with cytokines, clinical parameters, and the microbiome.

Results

During infection, peripheral tryptophan and kynurenine were elevated while indolelactate and xanthurenate were reduced ( p < 0.05). In the portal blood, kynurenine/tryptophan ratio and kynurenine were increased, whereas indoleacetate and xanthurenate were decreased ( p < 0.05). Tryptophan metabolites positively correlated with hepatic activity index, gamma‐glutamyl transferase, total bilirubin, spleen volume/height ratio, and pro‐inflammatory cytokines including CXCL9, CXCL10, TNFα, IL6, and IL‐12p40. Negatively, correlations were observed with gut microbes Dorea longicatena and Qiania dongpingenesis .

Conclusions

Elevated kynurenine in portal blood suggests upregulation of gut‐mediated pro‐inflammatory pathways during HCV infection. Integration of multi‐omics data from the gut‐liver axis highlights the contribution of the tryptophan pathway to inflammatory responses in HCV. However, small sample size, absence of quantitative values for all pathway metabolites, and reliance on correlative rather than causative associations limit mechanistic interpretation. Future studies with larger cohorts and functional analyses are needed to clarify causal mechanisms and evaluate therapeutic potential of targeting the tryptophan pathway. Trial Registration NCT02400216.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CHepatitis C, ChronicPortal VeinTryptophanAdultFemaleHumansMaleMiddle AgedAntiviral AgentsBiomarkersCytokinesGastrointestinal MicrobiomeKynurenineLiverSustained Virologic Response

Substanzen

Antiviral AgentsBiomarkersCytokinesKynurenineTryptophan

Autor:innen und Institutionen

  • Translational Hepatology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Jenna L Oringher, Elizabeth C Townsend, Gabriella M Quinn, Matthew G Menkart, David E Kleiner, Rabab O Ali, Theo Heller

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Oringher, J. L., Afruza, R., Chakraborty, M., Akiva, K. L., Zhang, G. Y., Townsend, E. C., Quinn, G. M., Scheuing, L., Menkart, M. G., Rai, A., Kleiner, D. E., Levy, E. B., Koh, C., Ali, R. O., Etzion, O., & Heller, T. (2026). Portal Vein Tryptophan Pathway Analysis Reveals Gut‐Mediated Inflammatory Pathway Predominance in HCV Infection. Liver International, 46(4). https://doi.org/10.1111/liv.70584

Vancouver

Oringher JL, Afruza R, Chakraborty M, Akiva KL, Zhang GY, Townsend EC, et al. Portal Vein Tryptophan Pathway Analysis Reveals Gut‐Mediated Inflammatory Pathway Predominance in HCV Infection. Liver International. 2026;46(4). doi:10.1111/liv.70584

BibTeX
@article{Oringher2026,
  author = {Oringher, Jenna L and Afruza, Rownock and Chakraborty, Moumita and Akiva, Kareen L and Zhang, Grace Y and Townsend, Elizabeth C and Quinn, Gabriella M and Scheuing, Lisa and Menkart, Matthew G and Rai, Anjali and Kleiner, David E and Levy, Elliot B and Koh, Christopher and Ali, Rabab O and Etzion, Ohad and Heller, Theo},
  title = {Portal Vein Tryptophan Pathway Analysis Reveals Gut‐Mediated Inflammatory Pathway Predominance in HCV Infection},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1111/liv.70584}
}
Kostenlos starten →